Umpierrez GE, Latif K, Stoever J, Cuervo R, Park L, Freire AX, et al
Mostafa T, Anis TH, Ghazi S, El-Nashar AR, Imam H, Osman IA
results varied across dose groups and this context is important when interpreting the data GI side effects were the most common adverse events, consistent with the GLP-1 class, and were predominantly mild to moderate in severity, declining over time Small increases in heart rate and gallbladder-related events were also observed, consistent with class effects The trial was of limited duration
Our fully virtual Weight Loss Care Plan includes: Personalised GP assessment Medication options like Wegovy Ongoing virtual check-ins Nutrition and lifestyle guidance Final Thoughts Both oral and injectable forms of semaglutide have the potential to support your weight loss journey but understanding the differences can help you commit to a plan that suits your life
You just need enough clarity to ask better questions, compare options wisely, and involve a trusted medical professional before making a decision
The full TRIUMPH program spans eight Phase 3 trials plus TRIUMPH-CVOT, enrolling more than 5,800 participants in the core weight-management trials and roughly 10,000 in the cardiovascular outcomes trial
